SGYP - Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company's product candidate is plecanatide, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant-irritable bowel syndrome (IBS-C). The Company is also developing SP-333, its second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone which is produced in the body's intestinal tract. The Company is preparing to initiate a Phase 2b clinical trial of plecanatide for the treatment of IBS-C in patients...

Synergy Pharmaceuticals Appoints Gail M. Comer, M.D. as Chief Medical Officer
3 days 12 hours 1 minutes ago - GlobeNewswire via Comtex
Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the appointment of Gail M. Comer, M. D. as Chief Medical Officer, effective May 14, 2012. In this newly created position, Dr. Comer will report directly to President and Chief Executive Officer, Gary S. Jacob, Ph.D., and will be responsible for guiding Synergy's clinical programs, including the ongoing Phase II/III study of plecanatide, the Company's leading drug candidate.

"Dr. Comer is a tremendous addition to our management team, and I am very pleased to welcome her to Synergy," said Dr. Jacob. "Dr. Comer has an extremely strong medical and academic background, along with extensive industry experience in clinical research."

Dr. Comer, a board-certified gastroenterologist and hepatologist, has more than 14 years of experience in the pharmaceutical industry, having spent 7 years at Abbott Laboratories as a Medical Director, six years in clinical development at Wyeth Research as Senior Medical Director, and most recently as Senior Director of the BioTherapeutics Research Unit at Pfizer. While at Wyeth, Dr. Comer was Medical Research Leader in Gastroenterology, and more recently, while at Pfizer, was Clinical Lead for multiple biologic compounds in early development in inflammatory bowel disease. Dr. Comer was an Associate Professor of Clinical Medicine at The State University of New York at Stony Brook prior to joining the pharmaceutical industry.

"Synergy's GC-C receptor agonist program represents an innovative and exciting technology platform that I believe offers great potential for the treatment of patients with GI disorders and diseases," said Dr. Comer. "I believe the depth of my experience in clinical development specifically in gastroenterology will play a pivotal role in maximizing Synergy's clinical potential with these drugs, and am very pleased and excited to be joining Synergy at this opportune time."

Aegis Capital acts as book-runner of Synergy Pharmaceuticals stock sale
1 days 12 hours 6 minutes ago - M2 via Comtex
4 May 2012 - Aegis Capital Corp is acting as the sole book-running manager for the offering of Synergy Pharmaceuticals Inc's (NASDAQ:SGYP) common stock, the US biopharmaceutical firm said today when it priced the deal. Roth Capital Partners has been hired as the lead manager, while Brean Murray Carret & Co and Summer Street Research Partners have been engaged as co-managers of the transaction. Synergy Pharmaceuticals priced its offer of 10m common shares at USD4.50 per share for gross proceeds of USD45m (EUR34m). The underwriters have been granted a 45-day over-allotment option to purchase up to 1.5m extra Synergy shares to cover excess demand, if any. The company, which develops medicines to treat gastrointestinal disorders and diseases, plans to use the net proceeds from the stock sale in support of its R&D activities, including its current Phase II/III clinical trial of plecanatide in chronic constipation patients and its Phase I clinical study of its second GC-C agonist SP-333. The net proceeds from the stock offering will also be used for general working capital and other corporate purposes. The offering is expected to be completed on 9 May 2012 after satisfaction of all requisite conditions. All of the stock in this offering will be sold by the company within its effective shelf registration and accompanying base prospectus on Form S-3.

Synergy Pharmaceuticals prices $45 million public offering
1 days 1 hours 3 minutes ago - Datamonitor Financial Deals Tracker via Comtex
Update on May 3, 2012:

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, has priced an underwritten public offering of 10 million shares of common stock at a price of $4.50 per share for total gross proceeds of $45 million.

Synergy has also granted the underwriters a 45-day option to purchase up to an additional 1.5 million shares of common stock to cover over-allotments, if any. The offering is expected to close on May 9, 2012.

Announcement (May 3, 2012):

Synergy Pharmaceuticals has commenced a public offering of its common stock.

Aegis Capital Corp. is acting as the sole book-running manager for the offering.

Deal Value (US$ Million) 45
Deal Type IPO
Sub-Category Pricing,Secondary Offering
Deal Status Announced: 2012-05-03
Deal Participants

Target (Company) Synergy Pharmaceuticals, Inc. (formerly Pawfect Foods, Inc.)
Deal Rationale

Synergy intends to use the net proceeds from this offering to fund its research and development activities, including its ongoing Phase II/III clinical trial of plecanatide and its Phase I clinical trial of SP-333, and for working capital and other general corporate purposes.

Offer Price ($ per share) 4.5
No. Shares Issued 10000000

secondary offering very sispicious IMO...
run it up the few weeks before offering pr so they can keep it at what it was prior to run incl new offering rather than drive it down with another offering from its pre run levels